FDA approves first membranous nephropathy drug
-
By
-
Mouj Hijazi
-
November 16, 2026
-
2 min
Clinical Scorecard: FDA approves first membranous nephropathy drug
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: FDA approves first membranous nephropathy drug |
| Key Mechanisms | Mechanisms or clinical associations described in the source article. |
| Target Population | Population described in the source article. |
| Care Setting | FDA-approved treatment to induce proteinuria remission in adults with primary membranous nephropathy at risk of disease progression; MAJESTY compared intravenous obinutuzumab with oral tacrolimus. |
Key Highlights
- Obinutuzumab (Gazyva) is the first FDA-approved treatment specifically indicated to induce remission of proteinuria in adults with primary membranous nephropathy at risk of progression.
- In the 142-participant MAJESTY trial, complete remission at week 104 occurred in 36.1% of obinutuzumab recipients and 5.7% of tacrolimus recipients.
- Overall remission at week 104 occurred in 50% of obinutuzumab recipients and 12.9% of tacrolimus recipients.
- The trial did not show a statistically significant difference in sustained eGFR decline of at least 30%; later endpoints in the prespecified testing hierarchy were not formally assessed for significance.
- FDA-identified common side effects included infusion-related reactions and upper respiratory tract infections; boxed warnings include hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.
Guideline-Based Recommendations
Diagnosis
- The MAJESTY trial defined complete remission at week 104 as a urine protein-to-creatinine ratio of 0.3 g/g or lower with stable eGFR, without rescue therapy, treatment failure, or early discontinuation.
Management
- Obinutuzumab is FDA-approved for adults with primary membranous nephropathy at risk of progression to induce remission of proteinuria.
- The MAJESTY trial compared intravenous obinutuzumab with oral tacrolimus, which was used off-label for this condition.
Monitoring & Follow-up
- Screen for hepatitis B before treatment and monitor for reactivation during and after treatment.
- Watch for symptoms of progressive multifocal leukoencephalopathy and manage infusion-related reactions.
Risks
- Obinutuzumab carries boxed warnings for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.
- Avoid administration in patients with active infections.
- In MAJESTY, grade 3 or higher adverse events occurred in 22% of obinutuzumab recipients and 19% of tacrolimus recipients; serious adverse events occurred in 17% and 14%, respectively.
Patient & Prescribing Data
Adults with primary membranous nephropathy at risk of disease progression.
In MAJESTY, 36.1% of patients receiving obinutuzumab achieved complete remission at week 104 versus 5.7% receiving tacrolimus; overall remission was 50% versus 12.9%. Common side effects reported by the FDA included infusion-related reactions and upper respiratory tract infections.
Clinical Best Practices
- Screen for hepatitis B before starting obinutuzumab and monitor for reactivation during and after treatment.
- Monitor for symptoms of progressive multifocal leukoencephalopathy and manage infusion-related reactions.
- Do not administer obinutuzumab to patients with active infections.
Related Resources & Content
Based on findings from:
FDA approves first membranous nephropathy drug
Mouj Hijazi. MDSpire News, 2026.
https://news.mdspire.com/internal-medicine/articles/fda-approves-first-membranous-nephropathy-drug/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.